CC 31244

Drug Profile

CC 31244

Alternative Names: CC-31244; NS5B NNI

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Cocrystal Discovery
  • Developer Cocrystal Pharma Inc
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis C

Most Recent Events

  • 16 Feb 2017 Interim efficacy and adverse events data from a phase Ia/Ib trial in Hepatitis C released by Cocrystal Pharma
  • 25 Apr 2016 Phase-I clinical trials in Hepatitis C in Canada (PO)
  • 15 Mar 2016 Cocrystal Pharma has issued and pending patents for NS5B NNI programmes in USA and Europe (Cocrystal Pharma, 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top